Mylan (MYL) Upgraded to B- at TheStreet
MYL has been the subject of several other research reports. Cowen reiterated a market perform rating and issued a $36.00 price objective (up previously from $30.00) on shares of Mylan in a research note on Thursday, October 5th. Mizuho restated a buy rating and set a $37.00 price target on shares of Mylan in a research note on Tuesday, October 24th. Zacks Investment Research lowered shares of Mylan from a buy rating to a hold rating in a research note on Wednesday, November 8th. Cantor Fitzgerald set a $41.00 price target on shares of Mylan and gave the stock a hold rating in a research note on Tuesday, December 26th. Finally, UBS Group set a $46.00 price target on shares of Mylan and gave the stock a buy rating in a research note on Monday, December 4th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $44.19.
Mylan (NASDAQ MYL) opened at $46.73 on Wednesday. Mylan has a 1 year low of $29.39 and a 1 year high of $47.25. The firm has a market cap of $25,067.65, a PE ratio of 9.94, a P/E/G ratio of 1.48 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.69% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. Meeder Asset Management Inc. boosted its holdings in Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after purchasing an additional 1,475 shares during the period. BT Investment Management Ltd bought a new position in Mylan in the 3rd quarter valued at $142,000. Doliver Capital Advisors LP bought a new position in Mylan in the 2nd quarter valued at $201,000. Charter Trust Co. bought a new position in Mylan in the 4th quarter valued at $226,000. Finally, Parametrica Management Ltd bought a new stake in shares of Mylan during the 3rd quarter worth $224,000. 74.90% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Mylan (MYL) Upgraded to B- at TheStreet” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/21/mylan-myl-upgraded-to-b-at-thestreet.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.